Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Myeloid neoplasms with isolated del(5q) and JAK2 V617F mutation: a grey zone combination of myelodysplastic and myeloproliferative features?

Sangiorgio VF, Geyer JT, Margolskee E, Al-Kawaaz M, Mathew S, Tam W, Orazi A.

Haematologica. 2019 Sep 26. pii: haematol.2019.227686. doi: 10.3324/haematol.2019.227686. [Epub ahead of print]

2.

Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with Increased blasts (<10%) or with other types of disease progression.

Geyer JT, Margolskee E, Krichevsky SA, Cattaneo D, Boiocchi L, Ronchi P, Lunghi F, Scandura JM, Ponzoni M, Hasserjian RP, Gianelli U, Iurlo A, Orazi A.

Haematologica. 2019 Sep 19. pii: haematol.2019.230193. doi: 10.3324/haematol.2019.230193. [Epub ahead of print]

3.

Chronic lymphocytic leukemia with TP53 gene alterations: a detailed clinicopathologic analysis.

Liu YC, Margolskee E, Allan JN, Mathew S, Bhavsar E, Casano J, Orazi A, Furman RR, Geyer JT.

Mod Pathol. 2019 Sep 2. doi: 10.1038/s41379-019-0356-z. [Epub ahead of print]

PMID:
31477813
4.

Incidence of noninvasive follicular thyroid neoplasm with papillary-like nuclear features and change in risk of malignancy for "The Bethesda System for Reporting Thyroid Cytology".

Sung S, Margolskee E, Chen D, Tiscornia-Wasserman P.

J Am Soc Cytopathol. 2019 May - Jun;8(3):133-140. doi: 10.1016/j.jasc.2019.01.005. Epub 2019 Jan 22.

PMID:
31097289
5.

Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.

Gomez-Arteaga A, Margolskee E, Wei MT, van Besien K, Inghirami G, Horwitz S.

Leuk Lymphoma. 2019 Jul;60(7):1626-1631. doi: 10.1080/10428194.2019.1594220. Epub 2019 Apr 18. No abstract available.

PMID:
30997845
6.

Cytological diagnosis of papillary thyroid carcinoma with tall cells on ThinPrep liquid-based cytology.

Baum JE, Soong L, Scognamiglio T, Margolskee EM, Hoda RS, Rao R.

Diagn Cytopathol. 2019 Jun;47(6):541-546. doi: 10.1002/dc.24146. Epub 2019 Jan 16.

PMID:
30648353
7.

The role of BRCA1-associated protein 1 in the diagnosis of malignant mesothelioma in effusion and fine-needle aspiration cytology.

Hatem L, McIntire PJ, He B, Gogineni S, Ho M, Mathew S, Margolskee EM, Siddiqui MT, Rao RA.

Diagn Cytopathol. 2019 Mar;47(3):160-165. doi: 10.1002/dc.24061. Epub 2018 Dec 6.

PMID:
30520251
8.

Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study.

Tang G, Sydney Sir Philip JK, Weinberg O, Tam W, Sadigh S, Lake JI, Margolskee EM, Rogers HJ, Miranda RN, Bueso-Ramos C C, Hsi ED, Orazi A, Hasserjian RP, Arber DA, Bagg A, Wang SA.

Mod Pathol. 2019 Apr;32(4):490-498. doi: 10.1038/s41379-018-0165-9. Epub 2018 Nov 6.

PMID:
30401948
9.

So-called "blast phase" of chronic myelomonocytic leukemia: a plea for uniform terminology.

Margolskee E.

Leukemia. 2018 Dec;32(12):2716. doi: 10.1038/s41375-018-0186-x. Epub 2018 Jun 28. No abstract available.

PMID:
29955129
10.

JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.

Aynardi J, Manur R, Hess PR, Chekol S, Morrissette JJD, Babushok D, Hexner E, Rogers HJ, Hsi ED, Margolskee E, Orazi A, Hasserjian R, Bagg A.

Br J Haematol. 2018 Jul;182(1):78-85. doi: 10.1111/bjh.15276. Epub 2018 May 16.

PMID:
29767839
11.

Pathogenesis of Peripheral T Cell Lymphoma.

Pizzi M, Margolskee E, Inghirami G.

Annu Rev Pathol. 2018 Jan 24;13:293-320. doi: 10.1146/annurev-pathol-020117-043821. Review.

PMID:
29414251
12.

A reevaluation of erythroid predominance in Acute Myeloid Leukemia using the updated WHO 2016 Criteria.

Margolskee E, Mikita G, Rea B, Bagg A, Zuo Z, Sun Y, Goswami M, Wang SA, Oak J, Arber DA, Allen MB, George TI, Rogers HJ, Hsi E, Hasserjian RP, Orazi A.

Mod Pathol. 2018 Jun;31(6):873-880. doi: 10.1038/s41379-018-0001-2. Epub 2018 Feb 5.

13.

Immunohistochemical staining for S100P, SMAD4, and IMP3 on cell block preparations is sensitive and highly specific for pancreatic ductal adenocarcinoma.

Sweeney J, Rao R, Margolskee E, Goyal A, Heymann JJ, Siddiqui MT.

J Am Soc Cytopathol. 2018 Nov - Dec;7(6):318-323. doi: 10.1016/j.jasc.2018.07.002. Epub 2018 Jul 7.

PMID:
31043302
14.

Bone marrow fibrosis in chronic myelomonocytic leukemia is associated with increased megakaryopoiesis, splenomegaly and with a shorter median time to disease progression.

Petrova-Drus K, Chiu A, Margolskee E, Barouk-Fox S, Geyer J, Dogan A, Orazi A.

Oncotarget. 2017 Oct 17;8(61):103274-103282. doi: 10.18632/oncotarget.21870. eCollection 2017 Nov 28.

15.

Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis.

Margolskee E, Hasserjian RP, Hassane D, Tam W, Mathew S, Ok CY, Wang SA, Oak J, Arber DA, Orazi A.

Am J Clin Pathol. 2017 Jul 1;148(1):49-57. doi: 10.1093/ajcp/aqx043.

PMID:
28927162
16.

Cytomorphologic features distinguishing Bethesda category IV thyroid lesions from parathyroid.

Sung S, Saqi A, Margolskee EM, Crapanzano JP.

Cytojournal. 2017 Apr 28;14:10. doi: 10.4103/1742-6413.205313. eCollection 2017.

17.

A Novel Variant t(1;22) Translocation - ins(22;1)(q13;p13p31) - in a Child with Acute Megakaryoblastic Leukemia.

Margolskee E, Saab J, Geyer JT, Aledo A, Mathew S.

Am J Case Rep. 2017 Apr 19;18:422-426.

18.

Targeted next generation sequencing of breast implant-associated anaplastic large cell lymphoma reveals mutations in JAK/STAT signalling pathway genes, TP53 and DNMT3A.

Di Napoli A, Jain P, Duranti E, Margolskee E, Arancio W, Facchetti F, Alobeid B, Santanelli di Pompeo F, Mansukhani M, Bhagat G.

Br J Haematol. 2018 Mar;180(5):741-744. doi: 10.1111/bjh.14431. Epub 2016 Nov 10. No abstract available.

PMID:
27859003
19.

Invasive granulomatous cryptococcal sinusitis in an adult with multiple myeloma.

Ferraro RA, Ivanidze J, Margolskee E, Tsang H, Sconomiglio T, Jhanwar YS.

Clin Imaging. 2017 Jan - Feb;41:65-68. doi: 10.1016/j.clinimag.2016.10.010. Epub 2016 Oct 17.

PMID:
27816878
20.

Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon α-treated polycythemia vera patients.

Margolskee E, Krichevsky S, Orazi A, Silver RT.

Haematologica. 2017 Mar;102(3):e97-e99. doi: 10.3324/haematol.2016.153973. Epub 2016 Nov 3. No abstract available.

21.

Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disorders.

Margolskee E, Jobanputra V, Jain P, Chen J, Ganapathi K, Nahum O, Levy B, Morscio J, Murty V, Tousseyn T, Alobeid B, Mansukhani M, Bhagat G.

Oncotarget. 2016 Jun 21;7(25):37636-37648. doi: 10.18632/oncotarget.9400.

22.

Clinicopathologic evaluation of cytopenic patients with isolated trisomy 8: a detailed comparison between idiopathic cytopenia of unknown significance and low-grade myelodysplastic syndrome.

Petrova-Drus K, Hasserjian R, Pozdnyakova O, Dal Cin P, Mathew S, Margolskee E, Orazi A, Geyer JT.

Leuk Lymphoma. 2017 Mar;58(3):569-577. doi: 10.1080/10428194.2016.1203432. Epub 2016 Jul 7.

PMID:
27389864
23.

Hepatocellular adenoma classification: a comparative evaluation of immunohistochemistry and targeted mutational analysis.

Margolskee E, Bao F, de Gonzalez AK, Moreira RK, Lagana S, Sireci AN, Sepulveda AR, Remotti H, Lefkowitch JH, Salomao M.

Diagn Pathol. 2016 Mar 9;11:27. doi: 10.1186/s13000-016-0475-5.

24.

Rosai-Dorfman Disease Harboring an Activating KRAS K117N Missense Mutation.

Shanmugam V, Margolskee E, Kluk M, Giorgadze T, Orazi A.

Head Neck Pathol. 2016 Sep;10(3):394-9. doi: 10.1007/s12105-016-0709-6. Epub 2016 Feb 27.

25.

Hypermetabolic residual retroperitoneal mass after chemotherapy for primary seminoma.

Pak JS, Shapiro E, Margolskee EM, McKiernan JM.

Urology. 2015 May;85(5):987-990. doi: 10.1016/j.urology.2015.01.016. Epub 2015 Mar 10. No abstract available.

PMID:
25769778
26.

Strategies for improving diagnostic accuracy of biliary strictures.

Salomao M, Gonda TA, Margolskee E, Eguia V, Remotti H, Poneros JM, Sethi A, Saqi A.

Cancer Cytopathol. 2015 Apr;123(4):244-52. doi: 10.1002/cncy.21509. Epub 2015 Jan 6.

27.

Indolent small intestinal CD4+ T-cell lymphoma is a distinct entity with unique biologic and clinical features.

Margolskee E, Jobanputra V, Lewis SK, Alobeid B, Green PH, Bhagat G.

PLoS One. 2013 Jul 4;8(7):e68343. doi: 10.1371/journal.pone.0068343. Print 2013.

Supplemental Content

Loading ...
Support Center